Immunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $58.89.

A number of brokerages have weighed in on IMCR. Needham & Company LLC reiterated a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a research note on Thursday, April 10th. Morgan Stanley restated an "equal weight" rating and issued a $35.00 price target on shares of Immunocore in a research report on Friday, March 7th. Oppenheimer lifted their price target on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Deutsche Bank Aktiengesellschaft began coverage on Immunocore in a research report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price objective on the stock. Finally, JPMorgan Chase & Co. decreased their price target on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, April 14th.

Insiders Place Their Bets

In related news, Director Bros. Advisors Lp Baker bought 807,338 shares of Immunocore stock in a transaction dated Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the transaction, the director now directly owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. The trade was a 60.40% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.40% of the company's stock.

Institutional Investors Weigh In On Immunocore

A number of large investors have recently added to or reduced their stakes in the company. Barclays PLC lifted its position in Immunocore by 2,044.0% during the 4th quarter. Barclays PLC now owns 20,625 shares of the company's stock valued at $608,000 after acquiring an additional 19,663 shares during the period. Legal & General Group Plc lifted its stake in Immunocore by 17.3% in the 4th quarter. Legal & General Group Plc now owns 136,875 shares of the company's stock worth $4,038,000 after purchasing an additional 20,163 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of Immunocore by 8.0% in the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock worth $78,722,000 after buying an additional 196,530 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Immunocore by 1.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock worth $64,533,000 after buying an additional 29,832 shares during the last quarter. Finally, BIT Capital GmbH boosted its holdings in Immunocore by 182.7% during the 4th quarter. BIT Capital GmbH now owns 67,840 shares of the company's stock valued at $2,001,000 after acquiring an additional 43,840 shares during the period. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Stock Performance

Immunocore stock traded down $0.77 during mid-day trading on Wednesday, reaching $37.25. 549,586 shares of the company traded hands, compared to its average volume of 370,661. The firm's fifty day moving average is $30.23 and its two-hundred day moving average is $30.20. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -39.21 and a beta of 0.83. Immunocore has a fifty-two week low of $23.15 and a fifty-two week high of $42.09. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.45. The firm had revenue of $125.13 million during the quarter, compared to the consensus estimate of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company's revenue for the quarter was up 33.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.49) EPS. On average, equities research analysts expect that Immunocore will post -0.94 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.